Allergic conjunctivitis secondary prevention

Jump to navigation Jump to search

Allergic conjunctivitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Allergic Conjunctivitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Allergic conjunctivitis secondary prevention On the Web

recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Allergic conjunctivitis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Allergic conjunctivitis secondary prevention

CDC on Allergic conjunctivitis secondary prevention

Allergic conjunctivitis secondary prevention in the news

Blogs on Allergic conjunctivitis secondary prevention

Directions to Hospitals Treating Allergic conjunctivitis

Risk calculators and risk factors for Allergic conjunctivitis secondary prevention

Overview

Secondary Prevention

Early diagnosis

The diagnosis should be confirmed and the severity assessed by a proper history and a thorough physical examination.

Treatment

The dual-activity agents are considered the appropriate first-line therapy. They are easily accessible and well tolerated. When symptoms and signs remain uncontrolled, a short course of topical ophthalmic steroids may be considered. As discussed above, monitoring by an eye care specialist is necessary when there is consideration to use this agent on a longer term basis. Other treatments include nasal steroids, oral anti-histamines and/or topical ophthalmic NSAIDs, which are listed in no particular order and can be used concomitantly. Topical calcineurin inhibitors can be used off-label by eyecare specialists as a next step. Immunotherapy, either subcutaneous or sublingual, can provide a longer term solution to the symptoms and signs of AC and can be considered when medical therapy is insufficient, poorly tolerated or for patient preference.

References

Template:WH Template:WS